We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
3.40 | 0.20% | 1,708.60 | 1,708.60 | 1,708.80 | 1,713.00 | 1,699.40 | 1,701.60 | 11,522,668 | 16:29:59 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.27 | 70.34B |
LONDON—GlaxoSmithKline PLC on Wednesday reported a sharp drop in net profit for the second quarter, reflecting the increased dominance of lower-margin vaccines and over-the-counter medicines in the company's portfolio following its $20 billion asset swap with Novartis AG.
The drug maker said net profit slid 77% to £ 149 million ($233 million) compared with the same period last year, despite a 6% rise in revenue to £ 5.89 billion, in the first full quarter since the Novartis transaction completed. Core operating profit, Glaxo's preferred measure, fell 4% to £ 1.35 billion, slightly higher than analysts' estimates of £ 1.34 billion. Stripping out the effect of the strong pound, revenue rose 7% and core operating profit increased by 3%.
Glaxo shares jumped about 3% after the release of the results.
Glaxo has become a lower-margin company following its $20 billion asset swap with Novartis, in which it traded its highly profitable oncology franchise for the Swiss company's vaccines business, which has slimmer margins. The pair also formed a joint venture, controlled by Glaxo, for their over-the-counter medicines, which also have lower margins than prescription pharmaceuticals.
Glaxo did the deal because it believes it will be better off in the long run with low-margin but high-demand vaccines than with high-margin but low-demand cancer drugs, especially as powerful drug buyers put downward pressure on prices.
Write to Denise Roland at Denise.Roland@wsj.com
Subscribe to WSJ: http://online.wsj.com?mod=djnwires
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions